Trial Profile
A Phase Ib/II Study of the ALK Inhibitor Ceritinib in Combination With the CDK4/6 Inhibitor LEE011 in Patients With ALK-positive Non-Small Cell Lung Cancer
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 19 May 2022
Price :
$35
*
At a glance
- Drugs Ceritinib (Primary) ; Ribociclib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 01 Apr 2022 Status changed to discontinued as per results published in the Lung Cancer
- 01 Apr 2022 Results published in the Lung Cancer
- 24 Aug 2018 Planned End Date changed from 18 Oct 2018 to 28 Sep 2018.